The Anti-Diabetic Drug Metformin Protects Against Chemotherapy-Induced Peripheral Neuropathy in a Mouse Model

DSpace/Manakin Repository

The Anti-Diabetic Drug Metformin Protects Against Chemotherapy-Induced Peripheral Neuropathy in a Mouse Model

Show full item record

Title: The Anti-Diabetic Drug Metformin Protects Against Chemotherapy-Induced Peripheral Neuropathy in a Mouse Model
Author(s):
Mao-Ying, Qi;
Kavelaars, Annemieke;
Krukowski, Karen;
Huo, Xiao-Jiao;
Zhou, Wenjun;
Price, Theodore J.;
Cleeland, Charles;
Heijnen, Cobi J.
Item Type: article
Keywords: Show Keywords
Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) characterized by loss of sensory sensitivity and pain in hands and feet is the major dose-limiting toxicity of many chemotherapeutics. At present, there are no FDA-approved treatments for CIPN. The anti-diabetic drug metformin is the most widely used prescription drug in the world and improves glycemic control in diabetes patients. There is some evidence that metformin enhances the efficacy of cancer treatment. The aim of this study was to test the hypothesis that metformin protects against chemotherapy-induced neuropathic pain and sensory deficits. Mice were treated with cisplatin together with metformin or saline. Cisplatin induced increased sensitivity to mechanical stimulation (mechanical allodynia) as measured using the von Frey test. Co-administration of metformin almost completely prevented the cisplatin-induced mechanical allodynia. Co-administration of metformin also prevented paclitaxel-induced mechanical allodynia. The capacity of the mice to detect an adhesive patch on their hind paw was used as a novel indicator of chemotherapy-induced sensory deficits. Co-administration of metformin prevented the cisplatin-induced increase in latency to detect the adhesive patch indicating that metformin prevents sensory deficits as well. Moreover, metformin prevented the reduction in density of intra-epidermal nerve fibers (IENFs) in the paw that develops as a result of cisplatin treatment. We conclude that metformin protects against pain and loss of tactile function in a mouse model of CIPN. The finding that metformin reduces loss of peripheral nerve endings indicates that mechanism underlying the beneficial effects of metformin includes a neuroprotective activity. Because metformin is widely used for treatment of type II diabetes, has a broad safety profile, and is currently being tested as an adjuvant drug in cancer treatment, clinical translation of these findings could be rapidly achieved. ;
Publisher: Public Library of Science
ISSN: 1932-6203
Persistent Link: http://dx.doi.org/10.1371/journal.pone.0100701
http://hdl.handle.net/10735.1/4098
Terms of Use: CC-BY 4.0 (Attribution)
Sponsors: US National Institutes of Health (PO1 CA124787; RO1 NS073939; RO1 NS74999; RO1 NS065926; RO1 GM102575)

Files in this item

Files Size Format View
BBS-FR-TJPrice-271104.60.pdf 809.7Kb PDF View/Open Article

This item appears in the following Collection(s)


Show full item record

CC-BY 4.0 (Attribution) Except where otherwise noted, this item's license is described as CC-BY 4.0 (Attribution)